This Cochrane review published on July, 17, 2009, identified one completed and one ongoing randomized controlled trial.
Of the completed trial, in which 30 patients received either 20 mg simvastatin or a placebo daily for a period of three months, the analyses did not show a statistically significant difference in visual acuity at completion of study treatment or 45 days after the completion of study treatment.
Of the ongoing trial, the preliminary analyses after 12 months of treatment did not show a statistically significant difference between 40 mg simvastatin daily and placebo in visual acuity, drusen score or visual function. Due to the small size of the completed trial and the short duration of the treatment and follow–up period, no conclusion regarding the effects of statins on the onset or progression of AMD can be made at this time. The authors will update this review as data from the ongoing trial become available.
Subscribe to:
Post Comments (Atom)
2 comments:
It seems that Big Pharma won't be happy until every man, woman and child are taking statin drugs.
Here is some additional information about the "genetics" of this condition that was written by our Genetic Counselor and other genetic professionals: http://www.accessdna.com/condition/Triploidy/374. I hope it helps. Thanks, AccessDNA
Post a Comment